Husten Acc Hexal Akut (Acetylcysteine)

Husten Acc Hexal Akut is indicated for mucolysis in several respiratory conditions where thick mucus impairs breathing, helping to improve airway clearance and reduce cough severity.

• Acute bronchitis with a productive cough, to loosen secretions and facilitate expectoration.
• Exacerbations of chronic obstructive pulmonary disease (COPD) where mucus retention contributes to dyspnea.
• Asthma episodes complicated by mucus plugging, supporting bronchodilator therapy.
• Pre‑operative or peri‑operative preparation to reduce airway secretions and lower the risk of postoperative pulmonary complications.
• Adjunct therapy in cystic fibrosis or other bronchopulmonary disorders to aid sputum clearance.

• Acetylcysteine acts as a mucolytic by cleaving disulfide bonds within the glycoprotein matrix of mucus. This reduction in sulfhydryl cross‑links decreases the viscosity and elasticity of bronchial secretions, allowing ciliary action and cough to transport the fluid more efficiently. The free sulfhydryl group also contributes to antioxidant activity, but the primary therapeutic effect in Husten Acc Hexal Akut is the physical thinning of mucus.

Adverse reactions to acetylcysteine are generally mild and reversible, though occasional serious events have been reported, particularly with rapid intravenous administration; oral use such as Husten Acc Hexal Akut shows a similar safety profile.

Common

• Nausea, abdominal discomfort, or a feeling of fullness.
• Vomiting, which may be transient and self‑limiting.
• Diarrhea or loose stools, usually mild.
• Skin reactions such as mild rash, itching, or erythema at the oral mucosa.
• Unpleasant odor or taste that may cause oral discomfort.

Serious

• Anaphylactoid reactions presenting as urticaria, angioedema, bronchospasm, or hypotension.
• Hepatic disturbances, including transient elevation of transaminases or jaundice.

When considering Husten Acc Hexal Akut, several precautionary measures should be observed to ensure safe use.

• Assess for known hypersensitivity to acetylcysteine or any excipients before initiating therapy.
• Use with caution in patients with active peptic ulcer disease, as gastrointestinal irritation may be exacerbated.
• Monitor liver function in individuals with pre‑existing hepatic impairment or chronic alcohol use.
• Avoid use in infants and young children unless directed by a healthcare professional, due to limited safety data.
• Consider potential bronchospasm in patients with severe asthma; discontinue if respiratory distress occurs.
• Pregnant or breastfeeding women should consult a physician, as safety data are insufficient.

Acetylcysteine may interact with certain medications, influencing their effectiveness or safety profile.

Avoid

• Concurrent use with nitroglycerin or other vasodilators, as acetylcysteine can potentiate hypotensive effects.
• Simultaneous administration of activated charcoal, which may adsorb the drug and reduce its absorption.

Use with caution

• Anticoagulants (e.g., warfarin), because mucolytic therapy may alter bleeding risk.
• Bronchodilators such as beta‑agonists; monitor for additive bronchospasm relief or irritation.
• Antibiotics that are excreted renally, as acetylcysteine may affect renal clearance.
• Other mucolytics or expectorants, to avoid excessive thinning of secretions.